In recent large randomized placebo-controlled trials, sodium–glucose cotransporter 2 (SGLT2) inhibitors were shown to decrease cardiovascular events, specifically secondary prevention and hospital admission for HF.20, 21, 22, 23, 24, 25, 26 Recent reviews have focused on the clinical benefits and mechanisms of the cardiorenal effects of SGLT2 inhibitors.27, 28, 29 In this review, the first part demonstrates the results of recent clinical trials and their clinical implications and outlines current trials and upcoming research areas. This evidence concerns the gene SLC5A2 and hydrops fetalis.